



CORRECTION

Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial

Hiroaki Seino

Published online: September 13, 2021
© The Author(s) 2021

Correction to: Diabetes Ther (2021) 12:863–877
<https://doi.org/10.1007/s13300-021-01014-0>

The original article has been published with some errors.

The correct Table 2, Fig. 2, and Fig. 3 are given below.

In the results section of Abstract, there is correction in the sentence, the correct sentence is “HOMA-IR significantly decreased but HOMA- β was unchanged. FLI, ferritin, M2-BP, NAFLD fibrosis scores, and FIB-4 index significantly decreased whereas type IV collagen 7S domain did not significantly change”.

In the Hepatic Function Biomarkers section of Results, the corrections in a sentence is “The

NAFLD fibrosis score and FIB-4 index significantly decreased from baseline to weeks 12, 24 and 52 (Table 2). The type IV collagen 7S domain did not significantly change from baseline”.

In the third paragraph of Discussion, the correct sentence is “Additionally, this study revealed improvement in the hepatic fibrosis biomarkers M2-BP, NAFLD fibrosis score, FIB-4 index, and ferritin following luseogliflozin administration in patients with T2DM complicated by hepatic dysfunction. However, type IV collagen 7S did not change significantly after luseogliflozin administration”.

The original article can be found online at <https://doi.org/10.1007/s13300-021-01014-0>.

H. Seino (✉)
Seino Internal Medical Clinic, Kaisei, Koriyama,
Fukushima, Japan
e-mail: kn7jh5@bma.biglobe.ne.jp

Table 2 Clinical outcomes







Endpoint	Week	Measurement		Change		
		<i>n</i>	Mean ± SD	<i>n</i>	Mean ± SD	<i>p</i> value
NAFLD fibrosis score	0	55	− 0.78 ± 1.07			
	12	53	− 0.92 ± 1.12	53	− 0.18 ± 0.55	0.0212
	24	52	− 1.03 ± 0.96	52	− 0.31 ± 0.63	0.0008
	52	49	− 0.99 ± 1.02	49	− 0.22 ± 0.52	0.0051
FIB-4 index	0	55	1.22 ± 0.67			
	12	54	1.06 ± 0.46	54	− 0.17 ± 0.40	0.0030
	24	52	1.01 ± 0.43	52	− 0.23 ± 0.43	0.0003
	52	49	1.04 ± 0.50	49	− 0.19 ± 0.33	0.0002
Type IV collagen 7S domain (ng/mL)	0	55	4.6 ± 1.2			
	24	52	4.6 ± 0.8	52	0.0 ± 1.0	0.8387
	52	49	4.6 ± 0.7	49	0.1 ± 1.0	0.4492
Ferritin (ng/mL)	0	55	191.4 ± 144.9			
	24	52	123.9 ± 113.2	52	− 64.6 ± 73.1	< 0.0001
	52	49	113.6 ± 97.9	49	− 76.9 ± 74.2	< 0.0001
hs-CRP (mg/dL)	0	55	0.12 ± 0.13			
	24	52	0.09 ± 0.10	52	− 0.02 ± 0.11	0.1222
	52	49	0.08 ± 0.11	49	− 0.03 ± 0.13	0.0968
IL-6 (pg/mL)	0	55	2.1 ± 2.7			
	52	49	1.6 ± 1.2	49	− 0.3 ± 1.1	0.0847
Body weight (kg)	0	55	80.4 ± 14.9			
	12	53	77.5 ± 14.0	53	− 1.9 ± 1.3	< 0.0001
	24	52	78.0 ± 14.0	52	− 2.6 ± 1.8	< 0.0001
	52	50	77.6 ± 14.2	50	− 3.1 ± 2.5	< 0.0001
BMI (kg/m ²)	0	55	29.2 ± 4.0			
	12	53	28.3 ± 4.0	53	− 0.7 ± 0.5	< 0.0001
	24	52	28.3 ± 3.8	52	− 0.9 ± 0.7	< 0.0001
	52	50	28.0 ± 3.8	50	− 1.1 ± 0.9	< 0.0001
Waist circumference (cm)	0	55	98.5 ± 9.9			
	12	53	97.0 ± 10.2	53	− 1.6 ± 3.0	0.0003
	24	52	97.2 ± 9.9	52	− 1.6 ± 3.2	0.0006
	52	47	96.7 ± 10.3	47	− 2.4 ± 3.2	< 0.0001
Systolic blood pressure (mm Hg)	0	55	131.9 ± 11.9			

Table 2 continued

Endpoint	Week	Measurement		Change		
		<i>n</i>	Mean ± SD	<i>n</i>	Mean ± SD	<i>p</i> value
Diastolic blood pressure (mmHg)	12	53	127.4 ± 11.6	53	− 4.4 ± 13.0	0.0172
	24	52	130.5 ± 11.2	52	− 1.0 ± 13.2	0.6019
	52	50	129.8 ± 12.5	50	− 1.9 ± 14.6	0.3565
	0	55	81.3 ± 9.5			
	12	53	79.2 ± 8.8	53	− 2.1 ± 9.4	0.1178
Pulse	24	52	78.7 ± 8.7	52	− 2.4 ± 9.4	0.0731
	52	50	79.8 ± 8.5	50	− 1.4 ± 10.2	0.3223
	0	53	75.0 ± 10.7			
	12	52	74.3 ± 11.8	50	− 0.3 ± 9.7	0.8163
	24	52	73.7 ± 11.6	50	− 1.3 ± 8.6	0.2809
Fasting plasma glucose (mg/dL)	52	48	73.8 ± 12.0	46	− 0.8 ± 8.1	0.4930
	0	55	148.8 ± 20.7			
	12	54	131.3 ± 17.7	54	− 17.9 ± 15.5	< 0.0001
	24	52	133.2 ± 23.5	52	− 16.8 ± 20.2	< 0.0001
	52	50	130.4 ± 19.8	50	− 18.8 ± 19.5	< 0.0001
Plasma insulin (μU/mL)	0	55	12.8 ± 7.0			
	12	53	10.9 ± 5.7	53	− 2.0 ± 4.6	0.0026
	24	52	11.0 ± 5.8	52	− 2.0 ± 5.0	0.0065
	52	49	11.1 ± 6.9	49	− 1.7 ± 5.4	0.0323
	HOMA-β (%)	0	55	55.6 ± 30.1		
12		53	59.3 ± 28.3	53	3.8 ± 25.3	0.2802
24		52	61.0 ± 32.1	52	5.7 ± 29.4	0.1710
52		49	61.5 ± 35.3	49	6.8 ± 26.0	0.0714
HOMA-IR		0	55	4.8 ± 2.7		
	12	53	3.6 ± 2.1	53	− 1.2 ± 1.7	< 0.0001
	24	52	3.7 ± 2.2	52	− 1.2 ± 1.8	< 0.0001
	52	49	3.6 ± 2.4	49	− 1.1 ± 2.2	0.0007

Data are presented as *n* and mean ± standard deviation

NAFLD fibrosis score nonalcoholic fatty liver disease fibrosis score, *FIB-4* fibrosis-4, *hs-CRP* high-sensitivity C-reactive protein, *IL-6* interleukin-6, *BMI* body mass index, *HOMA-β* homeostatic model assessment beta, *HOMA-IR* homeostatic model assessment of insulin resistance



Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated

otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.